Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes DOI Creative Commons
Du Zhi, Cheng Zhao,

Jiabin Li

и другие.

PeerJ, Год журнала: 2025, Номер 13, С. e19223 - e19223

Опубликована: Апрель 15, 2025

Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with poorly understood mechanisms. Variations in gut microbiota composition are observed different IBS subtypes. Ginsenosides have shown potential alleviating symptoms, but their interactions subtypes not well studied. Methods In this study, we investigated the effects of ginsenosides on both healthy participants and suffering from characterized by diarrhea (IBS-D) or constipation (IBS-C), using vitro fermentation alongside 16S rRNA sequencing bioinformatics analyses. Results The analysis demonstrated that there were no statistically significant alterations α- β-diversity between ginsenosides-treated control groups across all models. However, microbial assessment revealed presence 51 shared genera, notable variations enrichment specific taxa. Specifically, LEfSe that, following treatment, model exhibited Stenotrophomonas Achromobacter , while IBS-D Pseudomonas . Conclusions results elucidate distinctive signatures associated treatment groups, underscoring therapeutic efficacy modulating microbiota. This study highlights necessity for further investigation into targeted microbiome therapies IBS, which may facilitate development more personalized efficacious strategies health.

Язык: Английский

Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes DOI Creative Commons
Du Zhi, Cheng Zhao,

Jiabin Li

и другие.

PeerJ, Год журнала: 2025, Номер 13, С. e19223 - e19223

Опубликована: Апрель 15, 2025

Background Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with poorly understood mechanisms. Variations in gut microbiota composition are observed different IBS subtypes. Ginsenosides have shown potential alleviating symptoms, but their interactions subtypes not well studied. Methods In this study, we investigated the effects of ginsenosides on both healthy participants and suffering from characterized by diarrhea (IBS-D) or constipation (IBS-C), using vitro fermentation alongside 16S rRNA sequencing bioinformatics analyses. Results The analysis demonstrated that there were no statistically significant alterations α- β-diversity between ginsenosides-treated control groups across all models. However, microbial assessment revealed presence 51 shared genera, notable variations enrichment specific taxa. Specifically, LEfSe that, following treatment, model exhibited Stenotrophomonas Achromobacter , while IBS-D Pseudomonas . Conclusions results elucidate distinctive signatures associated treatment groups, underscoring therapeutic efficacy modulating microbiota. This study highlights necessity for further investigation into targeted microbiome therapies IBS, which may facilitate development more personalized efficacious strategies health.

Язык: Английский

Процитировано

0